N4-Phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease
- 1 November 2007
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (21) , 5783-5789
- https://doi.org/10.1016/j.bmcl.2007.08.050
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher diseaseProceedings of the National Academy of Sciences, 2007
- Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disordersExpert Opinion on Pharmacotherapy, 2007
- Development of Adamantan-1-yl-methoxy-Functionalized 1-Deoxynojirimycin Derivatives as Selective Inhibitors of Glucosylceramide Metabolism in ManThe Journal of Organic Chemistry, 2007
- Isofagomine- and 2,5-Anhydro-2,5-imino-d-glucitol-Based Glucocerebrosidase Pharmacological Chaperones for Gaucher Disease InterventionJournal of Medicinal Chemistry, 2006
- Rational Design and Synthesis of Highly Potent β‐Glucocerebrosidase InhibitorsAngewandte Chemie International Edition in English, 2005
- Gaucher Disease-Associated Glucocerebrosidases Show Mutation-Dependent Chemical Chaperoning ProfilesChemistry & Biology, 2005
- Synthesis of 2-[3,5-substituted pyrazol-1-yl]-4,6-trisubstituted triazine derivatives as antimalarial agentsBioorganic & Medicinal Chemistry Letters, 2005
- The cell biology of lysosomal storage disordersNature Reviews Molecular Cell Biology, 2004
- A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activityTrends in Pharmacological Sciences, 2003
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991